Today's Major Stories

Hurricane Melissa Makes Historic Landfall in Jamaica

Yesterday marked a devastating moment in Caribbean weather history as Hurricane Melissa slammed into Jamaica's southwest coast with catastrophic 185 mph winds. The Category 5 monster stands among the strongest Atlantic hurricanes ever recorded and represents the most powerful storm to strike Jamaica since officials began keeping records 174 years ago.

The immediate aftermath painted a grim picture: widespread power outages blanketed the island, roads became impassable, and damage assessment teams struggled to reach affected areas. Prime Minister Andrew Holness had issued stark warnings before the storm's arrival, emphasizing that Jamaica's infrastructure simply wasn't designed to handle such extreme forces.

What makes Melissa particularly alarming is how quickly it intensified. Over a single weekend, the storm's winds doubled from a manageable 70 mph to a terrifying 140 mph. This phenomenon, called rapid intensification, occurs when a storm's winds increase by at least 35 mph within 24 hours. Scientists point to warmer ocean waters as the primary fuel for this dangerous trend.

The numbers tell a concerning story: Caribbean waters in Melissa's path registered 2.5 degrees Fahrenheit warmer than historical averages for this time of year. This marks the fourth of five Atlantic hurricanes this season to undergo rapid intensification, suggesting a troubling pattern.

As of the latest reports, Melissa was tracking across southeastern Cuba with projected movement into the Bahamas by evening. Residents across the region remain on high alert as the powerful storm continues its destructive path.

 Texas Takes Legal Action Against Tylenol Makers

In a surprising legal move, Texas Attorney General Ken Paxton filed a major lawsuit against pharmaceutical giants Johnson & Johnson and Kenvue. The suit alleges these companies marketed Tylenol as safe for pregnant women while failing to disclose potential connections between acetaminophen use during pregnancy and neurodevelopmental disorders in children.

The legal action claims violations of consumer protection laws and references recent public statements from President Donald Trump and Health Secretary Robert F. Kennedy Jr. regarding pharmaceutical safety concerns.

Central to the lawsuit are claims that prenatal acetaminophen use may correlate with autism and ADHD. Paxton's team cites research from Harvard and Mount Sinai that identified correlations between prenatal exposure and these conditions. However, that same research explicitly stated it did not establish causation—a crucial distinction in scientific research.

The medical community has pushed back against these claims. Leading health experts and major medical organizations dispute the conclusions, maintaining that current scientific evidence doesn't support a causal link between acetaminophen use during pregnancy and neurodevelopmental disorders.

Adding complexity to the case, Johnson & Johnson transferred its consumer health business, including Tylenol, to Kenvue in 2023. Johnson & Johnson maintains it retains no liability for Tylenol products following this divestiture. The lawsuit counters that this corporate restructuring was designed to shield assets from legal claims.

Kenvue stands firm in its position that Tylenol remains safe for use during pregnancy when taken as directed.

OpenAI Completes Major Corporate Restructuring

Artificial intelligence powerhouse OpenAI announced completion of its multibillion-dollar reorganization, fundamentally transforming how the company operates and potentially setting the stage for a public stock offering.

The new corporate structure converts OpenAI into a for-profit public benefit corporation—the same model used by competitors Anthropic and xAI. This industry-standard arrangement makes it significantly easier for OpenAI to raise capital and pursue traditional business growth strategies.

Under the reorganized framework, operations split into two entities. The for-profit OpenAI Group PBC handles business operations, while a nonprofit arm called the OpenAI Foundation focuses on health and AI resilience initiatives. The Foundation holds a 26% stake in the for-profit entity, which, valued at $130 billion, makes it America's most valuable nonprofit organization—surpassing even the Gates Foundation's $86 billion valuation.

Microsoft maintains a 27% stake in the restructured company, though with modifications to their existing partnership agreement. The reorganization enabled OpenAI to secure $40 billion in promised funding from SoftBank and other major investors.

This marks the end of OpenAI's experimental governance structure, where a nonprofit board controlled for-profit business operations. The unusual arrangement had generated controversy and complications, making this restructuring a significant milestone in the company's evolution.